On April 6, 2026 Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, reported the close of a $100 million heavily oversubscribed Series A financing. The financing was co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners and GordonMD Global Investments, among others. In conjunction with the financing, Derek DiRocco, PhD and Thilo Schroeder, PhD will join the Stipple Bio Board of Directors which already includes Vineeta Agarwala MD, PhD, Owen Hughes, Jeff Landau and Aaron Ring MD, PhD and Greg Verdine, PhD.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proceeds from the financing, which should fund the company into 2029, will be used to advance its lead candidate, STP-100, into multiple early-stage clinical studies, and to leverage its Pointillist Platform to identify additional tumor-specific cell surface epitopes enabling the development of additional pipeline candidates with a high therapeutic index.

"We are building upon deep cancer biology expertise to map, target and unlock tumor-specific epitopes which enable us to develop a pipeline of next-generation precision oncology therapeutics," said Jeff Landau, Chief Executive Officer of Stipple Bio. "This funding positions us to progress STP-100 into the clinic and continue building a broad oncology pipeline. I am extremely pleased to have the support of industry-leading investors who share our enthusiasm towards developing precision and differentiated cancer therapies based on our modality-agnostic Pointillist Platform."

"Clinical experience with prior antibody drugs has taught us that epitope-level specificity matters. Since the earliest days of Stipple Bio, we’ve been impressed by the team’s vision to move beyond tumor-specific gene expression and to pioneer tumor-specific ‘epitomics’ in precision oncology. We are proud to have supported Stipple Bio since inception and to co-lead this financing as the company advances safer, more effective therapies for patients living with cancer," said Dr. Agarwala, General Partner at Andreessen Horowitz and lead investor for the a16z Bio+Health Fund.

"Stipple Bio’s Pointillist Platform introduces an epitope-level approach to targeting tumor biology that has the potential to meaningfully expand the set of druggable oncology targets. Lead candidate STP-100 illustrates how this strategy can drive precise tumor targeting while sparing normal tissues—a key step toward improving therapeutic index in ADCs. We are excited to partner with the team as they advance STP-100 into the clinic and build a broader pipeline from the platform," said Dr. DiRocco, Partner at RA Capital Management.

Stipple Bio was founded in 2022 by cancer biology pioneers Dr. Aaron Ring, Associate Professor, Translational Science and Therapeutics Division at Fred Hutch, and Dr. Aashish Manglik, Associate Professor, Pharmaceutical Chemistry at UCSF, both of whom believed that targeting tumor-specific cell surface epitopes could improve therapeutic index and unlock targets previously intractable with conventional oncology drug discovery methods. a16z Bio+Health, Emerson Collective Investments (managed by Yosemite) and OMX provided Stipple Bio’s initial Seed financing.

(Press release, Stipple Bio, APR 6, 2026, View Source [SID1234664197])

On April 6, 2026 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, reported that members of the management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

(Press release, Geron, APR 6, 2026, View Source [SID1234664196])

On April 6, 2026 Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, reported that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the 25th Annual Needham Virtual Healthcare Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026
Event details:
Date: Wednesday, April 15, 2026
Time: 3:00pm ET
Location: Virtual

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

(Press release, Verrica Pharmaceuticals, APR 6, 2026, View Source [SID1234664195])

On April 6, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") reported a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q1 2026 Highlights

Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter.
FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed.
Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-quarter. Strong revenue growth in both Illuccix and Gozellix segments.
ProstACT Global Phase 3 study of TLX591-Tx prostate cancer therapy candidate: Part 1 lead-in met safety and dosimetry objectives, with no new safety signals observed1.
TLX101-Px (brain cancer imaging candidate): New Drug Application (NDA) resubmitted to the United States (U.S.) Food and Drug Administration (FDA)2 for Pixclara3. Marketing Authorization Application (MAA) filed in Europe4 for Pixlumi3.
TLX591-Px5: NDA accepted in China by the National Medical Products Administration (NMPA)6.

Q1 2026 Revenue (Unaudited)

Revenue (US$M) Q1 2026 Q1 2025 Variation Q4 2025 Variation
Group revenue 230 186 24% 208 11%
Precision Medicine revenue7 186 151 23% 161 16%
TMS third-party revenue8 44 34 29% 44 —%

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, "Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two‑product PSMA9 imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter."

Therapeutics Business Unit

Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q1 2026 highlights include:

TLX591-Tx (lutetium (177Lu) rosopatamab tetraxetan): Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate, achieved its study objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed1. No adverse drug-drug interactions were observed in TLX591-Tx combinations, demonstrating the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC10, including ARPIs11 (enzalutamide or abiraterone) and docetaxel. Telix has commenced engagement with the FDA to present data from Part 1 and ascertain eligibility for U.S. patients to participate in Part 2 (randomized treatment expansion). Part 2 is open for enrollment in Australia, New Zealand and Canada, with site activation underway in preparation to open enrollment in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan, where regulatory approvals have already been granted.
TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan): Telix has opened its first clinical site and is recruiting patients for Part 1 of LUTEON12, a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC13. Trial recruitment will initially focus ex-U.S.
TLX101-Tx (131I-iodofalan): Telix has enrolled the first patient in IPAX-BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma14. The trial is now open for enrollment in Australia, Austria and the Netherlands and has received regulatory approval to commence in Belgium.
TLX090-Tx (153Sm-DOTMP): Telix continues to dose patients in SOLACE15, a Phase 1 study of a drug candidate for treating pain in patients with osteoblastic bone metastases from prostate and breast cancers. The study was expanded this quarter to include additional U.S. sites to accelerate recruitment.
TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA): TLX597-Tx is a "next generation" PSMA-targeting prostate cancer therapy candidate being developed to facilitate patient access in select geographies, where routine clinical availability to approved therapies is limited or not available. Early clinical data suggests a favorable asset biodistribution with limited uptake in healthy organs of concern (e.g., salivary glands, kidneys) relative to available 177Lu-PSMA therapies. Interim data from OPTIMAL-PSMA16, an investigator-led, randomized, dose intensification study of TLX597-Tx in mCRPC, will be presented at the International Prostate Cancer Symposium in April 2026.

Precision Medicine Business Unit

PSMA imaging portfolio:

Telix continues to expand its commercial footprint with Illuccix now launched in 21 countries globally, which includes 16 countries in Europe. This growing international presence enhances access to PSMA-PET/CT imaging17 while establishing a scalable commercial and operational platform to support future product launches, including follow-on therapeutic products.
Telix’s broad proposed label for TLX591-Px (Illuccix) is under review by the NMPA Centre for Drug Evaluation as part of the NDA submission18.

TLX101-Px, (Floretyrosine F 18 or 18F-FET):

Telix has resubmitted its NDA in the U.S. with the additional clinical data and analysis as agreed with the FDA.
Telix has submitted a MAA in Europe covering commercially significant markets, seeking to expand patient access to advanced brain imaging.

Zircaix3 (TLX250-Px, 89Zr-DFO-girentuximab):

Based on two successful Type A meetings with the FDA, Telix believes it has aligned on key outstanding issues for the Biologics License Application (BLA) resubmission, including demonstration of drug product comparability between clinical trial material and scale-up commercial production. The Company is now completing the agreed deliverables and documentation required, targeting a H1 2026 submission.

Corporate Updates

Telix has announced the appointment of David Gill as Non-Executive Director (NED), effective May 11, 2026, as part of its Board renewal process19. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as NED. The Board believes Mr. Gill’s appointment will enhance the Board’s capability, with extensive experience in U.S. public company governance, financial oversight and senior leadership across commercial and clinical-stage biopharmaceutical companies.

FY 2026 guidance

Telix reaffirms FY 2026 revenue guidance of US$950 million to US$970 million20.
Guidance reflects revenue from product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS.
Telix reaffirms research and development (R&D) expenditure guidance of US$200 million to US$240 million, subject to achieving ongoing global commercial milestones.

(Press release, Telix Pharmaceuticals, APR 6, 2026, View Source [SID1234664194])

On April 6, 2026 Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, reported that it will present three posters at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, which is being held from April 17-22, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentations will include preclinical data for the company’s two lead programs, FX-909, a first-in-class, orally available PPARG inhibitor designed to target the underlying luminal lineage biology of urothelial cancer and FX-111, a novel and highly differentiated potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor for prostate cancer.

FX-909 Presentation Details:

Luminal urothelial carcinoma (UC), characterized by high PPARG expression, represents the majority of UC cases and is associated with poor clinical outcomes. In a Phase 0 study, FX-909, a first-in-class oral PPARG inhibitor, demonstrated intratumoral penetration and on-target activity, including dose-dependent PPARG modulation, increased tumor apoptosis, and enhanced CD8⁺ T-cell infiltration. Notably, combination with anti-PD-1 further amplified immune activation and suppression of tumor proliferation pathways. These findings support the potential of FX-909 to modulate the tumor microenvironment and warrant further clinical evaluation in UC.

Title: Phase 0 Intratumoral Microdevice Study of FX-909 in Bladder Cancer Demonstrates On-Target Anti-Tumor Activity and Immune Modulation, Enhanced in Combination with Anti-PD-1

Abstract ID: CT111 / 3
Session: Phase 0 and First-in-Human Phase I Clinical Trials
Date, Time: April 20, 2026, 2:00 p.m. – 5:00 p.m. PT
Location: Section 51
FX-111 Presentation Details:

Metastatic castration-resistant prostate cancer (mCRPC) remains largely driven by androgen receptor (AR) signaling, with resistance to current AR inhibitors posing a major clinical challenge. Real-world data identified distinct AR/KLK3-defined subgroups, with AR copy number amplification linked to increased AR signaling and poorer outcomes, reinforcing the central role of AR-driven biology in disease progression and identifying a high-risk, AR-driven population.

Title: AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC)

Abstract ID: 3910 / 16
Session: Molecular Targeted Therapy
Date, Time: April 20, 2026, 2:00 p.m. – 5:00 p.m. PT
Location: Section 47
FX-111 is a novel and highly differentiated, potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor. This approach offers the potential to overcome key vulnerabilities of conventional therapies that target AROFF, particularly in high-risk AR-driven disease, and has broad potential across prostate cancer at all stages.

Title: Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androgen receptor (ARON), to treat patients with AR-driven prostate cancer

Abstract ID: 5784 / 11
Session: Proximity-Induced Drug Discovery 2
Date, Time: April 21, 2026, 2:00 p.m. – 5:00 p.m. PT
Location: Section 15

(Press release, Flare Therapeutics, APR 6, 2026, View Source [SID1234664193])